
    
      This is a phase II, multicenter, open-label, randomized, comparator-controlled study to
      evaluate the efficacy and safety of Pegylated Interferon -Î±2b in the treatment of adult
      patients diagnosed with SARS-CoV2 (COVID-19).Moderate COVID-19 subjects will be randomly
      assigned to receive test arm or reference arm in a 1:1 ratio.
    
  